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Transient phosphorylation of the a-subunit of translation
initiation factor 2 (eIF2a) represses translation and acti-
vates select gene expression under diverse stressful con-
ditions. Defects in the eIF2a phosphorylation-dependent
integrated stress response impair resistance to accumula-
tion of malfolded proteins in the endoplasmic reticulum
(ER stress), to oxidative stress and to nutrient depriva-
tions. To study the hypothesized protective role of eIF2a
phosphorylation in isolation of parallel stress signaling
pathways, we fused the kinase domain of pancreatic
endoplasmic reticulum kinase (PERK), an ER stress-
inducible eIF2a kinase that is normally activated by
dimerization, to a protein module that binds a small
dimerizer molecule. The activity of this artificial eIF2a
kinase, Fv2E-PERK, is subordinate to the dimerizer and is
uncoupled from upstream stress signaling. Fv2E-PERK
activation enhanced the expression of numerous stress-
induced genes and protected cells from the lethal effects of
oxidants, peroxynitrite donors and ER stress. Our findings
indicate that eIF2a phosphorylation can initiate signaling
in a cytoprotective gene expression pathway indepen-
dently of other parallel stress-induced signals and that
activation of this pathway can single-handedly promote a
stress-resistant preconditioned state.
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Introduction
Four protein kinases are known to couple the otherwise
unrelated stresses of protein malfolding in the endoplasmic
reticulum (ER) (Ron and Harding, 2000), amino acid depriva-
tion (Hinnebusch, 2000), viral infection (Kaufman, 2000)
and heme deficiency (Chen, 2000) to the phosphorylation
of translation initiation factor 2 on serine 51 of its alpha
subunit (eIF2a). This results in inhibition of the guanine
nucleotide exchange factor of the eIF2 complex, repressing
mRNA translation and protein synthesis (Hinnebusch, 2000;
Dever, 2002). At the same time the translation of activating
transcription factor 4 (ATF4) mRNA is specifically increased
(Harding et al, 2000a). We have recently discovered that
ATF4 plays an important role in activating genes that promote
the linked processes of import and metabolism of thiol-
containing amino acids and resistance to oxidative stress.
Because it integrates signaling in diverse stressful conditions,
we refer to this eIF2a phosphorylation-dependent, stress-
inducible pathway as an integrated stress response (ISR)
(Harding et al, 2003).
Various lines of evidence point to a possible role for eIF2a
phosphorylation in promoting resistance to cellular stresses.
Mutations in the upstream eIF2a kinases pancreatic endo-
plasmic reticulum kinase (PERK) and GCN2 compromise
resistance to ER stress and nutritional deprivation, respec-
tively (Harding et al, 2000b; Harding et al, 2001; Zhang et al,
2002a, b), and replacing serine 51 in eIF2a with an alanine,
a mutation that precludes phosphorylation by the stress-
activated kinases, also markedly sensitizes cells to stress
(Scheuner et al, 2001). In other pathophysiological contexts,
it has been noted that cerebral ischemia results in profound
but transient eIF2a phosphorylation and activates some of
the target genes of the ISR (DeGracia et al, 2002). The latter
process has been linked to the activity of the eIF2a kinase
PERK (Kumar et al, 2001), which promotes resistance to the
stress of malfolded proteins in the ER. Hibernation in mam-
mals, which is one of the most stress-resistant states of the
central nervous system, is associated with very high levels
of eIF2a phosphorylation (Frerichs and Hallenbeck, 1998;
Frerichs et al, 1998). Lastly, stable genetic manipulations
that constitutively reduced the activity of the eIF2 complex
(and thereby phenocopy the effects of eIF2a phosphoryla-
tion) induce a state of resistance to oxidative glutamate
toxicity in an immortalized mouse hippocampal cell line
(Tan et al, 2001).
It has long been known that low levels of stress that
activate downstream signaling pathways without causing
severe cell injury can protect against subsequent exposure
to more severe stress. This phenomenon is referred to as
preconditioning and has a significant heterologous compo-
nent such that the preconditioning stimulus and the subse-
quent stress may be very different in nature. Pathways, such
as the ISR, that couple diverse stressful conditions to a
common downstream event (eIF2a phosphorylation) are
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candidates for having a role in heterologous preconditioning.
This idea is further supported by the aforementioned study
of Schubert and colleagues, which demonstrated a protective
role for stable genetic manipulations that reduce the activity
of the eIF2 complex (Tan et al, 2001). However, as the
conditions known to activate eIF2a kinases are invariably
stressful, it has not been possible to segregate the contribu-
tion of other parallel signaling pathways that operate along-
side eIF2a phosphorylation from the contribution of eIF2a
phosphorylation to heterologous preconditioning. Nor is it
known which, if any, of the components of the ISR can be
activated purely by eIF2a phosphorylation. These questions
are relevant both to understanding the details of signaling
pathways operative during cell stress and to the practical
issue of identifying components of these pathways that might
serve as useful targets for interventions to promote pharma-
cological preconditioning.
To determine if signaling by phosphorylated eIF2a and
activation of the ISR may be harnessed to promote precondi-
tioning, we have created a genetic system for inducing rapid
reversible phosphorylation of eIF2a independently of cell
stress and examined its impact on the susceptibility of
cultured cells to diverse stressful conditions.
Results
Stress associated with eIF2a phosphorylation protects
HT22 cells against oxidative glutamate toxicity
Extracellular glutamate depletes intracellular cysteine and
glutathione, leading to oxidative glutamate toxicity (Murphy
et al, 1989), a process believed to play a role in neuronal cell
death mediated by extracellular glutamate (Schubert and
Piasecki, 2001). HT22 cells are an immortal mouse hippo-
campal cell line that is resistant to glutamatergic excitotoxi-
city but susceptible to oxidative glutamate toxicity and
represents a useful model system for studying cellular re-
sponses to oxidative stress (Morimoto and Koshland, 1990;
Maher and Davis, 1996; Tan et al, 2001). To test the hypoth-
esis that eIF2a phosphorylation and activation of the ISR
promotes resistance to oxidative glutamate toxicity, we first
measured the ability of manipulations known to promote
eIF2a phosphorylation to protect HT22 cells from the lethal
effects of glutamate. Pretreatment of HT22 cells with tunica-
mycin or thapsigargin, ER stress-inducing agents that cause
eIF2a phosphorylation and activate the ISR (Harding et al,
2003), was protective against subsequent challenge with
glutamate (Figure 1A).
The stress paradigm used, 1 h treatment with the ER stress-
inducing drug followed by 5 h recovery before exposure to
glutamate, was sufficient to induce both eIF2a phosphoryla-
tion and subsequent expression of the ISR targets ATF4,
GADD34 and CHOP (Figure 1B). The survival benefit was
dose-dependent and the protective effect of the different
stressors correlated with their ability to promote eIF2a phos-
phorylation (data not shown). The brief interval between the
preconditioning ER stress and application of glutamate favors
a true survival advantage afforded by the preceding stress
and discounts selection for stress-resistant cells and their
proliferation at the expense of a susceptible sub-population
as the basis for the increased survival of the pretreated cells.
We conclude that stressful manipulations that increase the
level of phosphorylated eIF2a promote resistance to gluta-
mate toxicity in HT22 cells.
To further examine the correlation between eIF2a phos-
phorylation and resistance to glutamate, we measured the
impact of blocking eIF2a phosphorylation in HT22 cells. To
this end, we overexpressed an activated form of GADD34,
the regulatory subunit of an eIF2a-specific holophosphatase
complex, in HT22 cells (Novoa et al, 2001). As predicted,
HT22 cells that stably overexpressed an active fragment of
GADD34 had no detectable phosphorylated eIF2a under basal
conditions or when stressed (Figure 2A). Inhibition of eIF2a
phosphorylation markedly compromised cell survival in reg-
ular media. However, the defect was rescued by adding the
reducing compound b-mercaptoethanol (bME) to the media
(Figure 2B and C). These observations indicate a role for
eIF2a phosphorylation in the basal resistance of HT22 cells
to oxidative stress and are consistent with the phenotype of
mouse embryonic fibroblasts (MEFs) with a compromised
ISR (Harding et al, 2003).
Cells cultured in media containing anti-oxidants such as
bME are resistant to cell death induced by 5mM glutamate
(Miyamoto et al, 1989; Davis and Maher, 1994) (and data not
shown). However, we found that susceptibility to glutamate
toxicity could be restored if cells previously growing in the
media containing bME were switched to media lacking bME
during the exposure to glutamate. About 20% of parental
Figure 1 Stresses that promote eIF2a phosphorylation protect
HT22 cells from glutamate-induced cell death. (A) Survival of
HT22 cells pretreated for 1 h with thapsigargin or tunicamycin
followed by 5h of recovery and subsequent challenge with 5mM
glutamate (closed squares) or 10mM glutamate (open squares) for
24 h. Survival is expressed as a percentage of MTT reduced by
glutamate-treated cells in each pretreatment group compared with
MTT reduction by cells subjected to the same pretreatment but not
exposed to glutamate. Values shown are the mean and SEM from a
representative experiment performed in triplicate and reproduced
twice. (B) Immunoblots of cytoplasmic extracts incubated with
antisera specific for phosphorylated eIF2a (eIF2a-P), total eIF2a
and GADD34 and of nuclear extracts incubated with antisera to
ATF4 and CHOP from untreated HT22 cells, or cells treated with
thapsigargin (Tg, 0.5 mM) or tunicamycin (Tm, 0.3 mg/ml) for 0.5 or
1 h and after 5 h of recovery (R).
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HT22 cells, previously cultured in bME, were dead after 24 h
exposure to 5mM glutamate in media lacking bME
(Figure 2D). This compared with B65% death following
a similar exposure in cells that had not been cultured
previously in bME -containing media (Figures 1A and 4C).
In this paradigm of switch from bME (þ ) to bME (),
GADD34-overexpressing HT22 cells were hypersensitive to
cell death induced by glutamate treatment. Only 70% of such
cells survived 24 h exposure in 2mM glutamate, as compared
to 100% survival of the inactive GADD34DC-overexpressing
control cells or cells transduced with empty vector. Following
exposure to 5mM glutamate, there was 36% survival of
GADD34-overexpressing HT22 cells compared with approxi-
mately 80% survival in the control cell lines (Figure 2D).
Withdrawal of the bME for the period of time used for
glutamate exposure did not compromise survival of the
GADD34-expressing HT22 or the control cells (data not
shown). This experiment indicates that blocking eIF2a phos-
phorylation sensitizes HT22 cells to oxidative glutamate
toxicity.
A ligand-activated eIF2a kinase that promotes
conditional translational inhibition and downstream
target gene expression
The experiments described above establish a correlation
between eIF2a phosphorylation and resistance to oxidative
glutamate toxicity. However, many signaling pathways are
activated in stressed cells and it was therefore impossible to
attribute the protective effect of the preconditioning preced-
ing stress specifically to eIF2a phosphorylation and activation
of the ISR. To uncouple eIF2a phosphorylation from stress,
we took advantage of the fact that activation of PERK is
initiated by oligomerization, which leads to trans-autophos-
phorylation and increased ability to phosphorylate its sub-
strate, eIF2a. Normally, this oligomerization event is driven
by the stress-sensing ER lumenal domain of PERK; however
PERK activation can be subordinated to any heterologous
oligomerization domain (Bertolotti et al, 2000; Liu et al,
2000). Therefore, we fused the eIF2a kinase effector domain
of PERK to a polypeptide containing two modified FK506
binding domains (Fv2E) and expressed the fusion protein,
Fv2E-PERK, as a soluble cytoplasmic protein in HT22 cells
(Figure 3A). The modified FKBP domain (Fv2E) is a high-
affinity receptor for a cell-permeant synthetic small organic
molecule, AP20187, that can be engaged simultaneously
by two modified Fv2E domains (Spencer et al, 1993). The
bivalent ligand thereby serves as a dimerizer/oligomerizer,
and when added to cells can induce clustering of Fv2E-
containing fusion proteins.
Because it lacks an ER lumenal domain, Fv2E-PERK does
not respond to ER stress but allows for drug-induced activa-
tion of the eIF2a kinase domain of PERK without subjecting
the cells to ER stress. Addition of AP20187 to Fv2E-PERK-
expressing HT22 cells resulted in rapid activation of the
kinase as reflected in a shift to a slower mobility trans-
autophosphorylated form (Figure 3B). Fv2E-PERK remains
phosphorylated for the duration of exposure of cells to
AP20187. Furthermore, phosphorylation of endogenous
eIF2a approaches saturation within 15min and expression
of the ISR target genes, GADD34 and CHOP, was observed
within 2 h of drug treatment. AP20187 has no impact on
eIF2a phosphorylation or target gene expression in parental
Figure 2 Impaired eIF2a phosphorylation sensitizes HT22 cells to
oxidative glutamate toxicity. (A) Immunoblot of phosphorylated
eIF2a (eIF2a-P) and total eIF2a from cempty, GADD34 or GADD34DC
cells treated with 400nM thapsigargin (Tg) for the indicated time.
(B) Photomicrograph of crystal-violet-stained HT22 cells transduced
with retroviruses expressing an activated form of an eIF2a phos-
phatase (GADD34), an inactive mutant (GADD34DC) or the empty
vector (cempty). Following transduction, cells were plated at clonal
density and cultured in regular media or media supplemented with
the reducing compound bME for 6 days prior to staining. (C)
Photomicrograph of crystal-violet-stained HT22 cells selected for
stable expression of GADD34, cempty or GADD34DC and plated at
clonal density regular in media or media containing bME. (D)
Survival of HT22 GADD34, cempty or GADD34DC cells following
24 h of exposure to glutamate in media lacking bME. 100% survival
is defined as the MTT reduction by cells of each line that had not
been exposed to glutamate. The graph shown represents a typical
experiment performed in duplicate and reproduced twice.
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HT22 cells lacking Fv2E-PERK (Figure 3B), and Fv2E-PERK
does not require endogenous PERK for its activity nor does
it activate endogenous PERK (see below, Figure 6B). As
expected, treatment of Fv2E-PERK-expressing cells with
AP20187 also results in translational inhibition demonstrated
by reduced 35S-methionine incorporation into newly synthe-
sized protein. The magnitude of the reduction is similar to
those observed in ER stressed cells (Figure 3C).
The Fv2E-PERK transgenic cells allowed us to survey the
gene expression program activated by an eIF2a kinase under
conditions in which parallel stress-induced signaling path-
ways were not activated. To facilitate comparison between
the profiles of genes expressed in AP20187-treated Fv2E-
PERK cells and a previously performed survey of the ISR
(Harding et al, 2003), we carried out the expression micro-
array analysis in Fv2E-PERK containing MEFs (see below,
Figure 6). The mRNA level of 506 genes was increased two-
fold or more at 4 or 8 h following AP20187 treatment,
compared with the untreated Fv2E-PERK positive cells
(Figure 3E and Table I).
This AP20187-dependent response overlapped with the
response to the ER stress-inducing drug tunicamycin.
Furthermore, the overlap between the two responses sub-
stantially coincided with the portion of the ER stress response
that is dependent on eIF2a phosphorylation, as it is compro-
mised in Perk/ cells (Figure 3E, Group A, Table I). This
subset of genes encodes enzymes involved in amino acid
metabolism, thiol metabolism and sufficiency, and resistance
to oxidative and other cellular stresses (Table I): all recog-
nized target genes of the ISR. Remarkably, many genes
encoding ER chaperones and other classical targets of the
ER stress response such as genes involved in protein degra-
dation were also activated by Fv2E-PERK. The latter observa-
tions are consistent with a prominent role of eIF2a
phosphorylation in controlling such classic unfolded protein
response genes, which was revealed previously by analysis of
Figure 3 Uncoupling the eIF2a kinase activity of PERK from its activation by ER stress. (A) Schematic representation of the Fv2E-PERK fusion
protein. The modified FKBP domains (Fv) and the transmembrane domain of PERK (TM) are indicated. (B) Immunoblot of Fv2E-PERK,
phosphorylated (eIF2a-P) and total eIF2a, and the downstream targets GADD34 and CHOP in lysates of Fv2E-PERK-expressing HT22 cells and
parental HT22 cells following treatment with 1 nM of the AP20187 dimerizer or thapsigargin (Tg). The position of the activated and
phosphorylated (Fv2E-PERKP) and the inactive hypophosphorylated Fv2E-PERK (Fv2E-PERK0) are indicated. (C) Autoradiogram of 35S-
methionine incorporation into newly synthesized proteins in Fv2E-PERK-expressing HT22 cells that had been left untreated (UT) or had been
treated with 1 nM AP20187 for 1 h or 400nM thapsigargin (Tg) for 0.5 h. (D) Immunoblot of Fv2E-PERK, phosphorylated (eIF2a-P) and total
eIF2a, and the downstream targets GADD34 and ATF4 in lysates of Fv2E-PERK-expressing MEFs with wild-type (S/S) and mutant (A/A) eIF2a
genotypes, following treatment with 2 nM of the AP20187 dimerizer. (E) Microarray analysis of the expression level of ISR target genes in Fv2E-
PERK MEFs with wild-type (S/S) and mutant (A/A) eIF2a genotypes. The 375 genes induced at least two-fold in both AP20187-treated Fv2E-
PERK MEFs (at either 4 or 8 h) and tunicamycin-treated wild-type MEFs or in tunicamycin-treated MEFs alone are shown. The expression levels
of the genes are shaded, with white indicating low levels of expression and black indicating high levels of expression. The genes are clustered to
reveal a group of PERK-dependent tunicamycin-induced genes that are also activated by Fv2E-PERK (Group A) and a group of PERK-dependent
tunicamycin-induced genes that are not induced by Fv2E-PERK activation (Group B).
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cells with mutations affecting the ISR (Scheuner et al, 2001;
Harding et al, 2003) (Table I).
To determine directly the role of eIF2a phosphorylation in
activated gene expression by Fv2E-PERK, we expressed the
chimeric protein in fibroblasts derived from mouse embryos
homozygous for a serine 51 to alanine mutation of endogen-
ous eIF2a gene (eIF2aA/A, the wild type being eIF2aS/S). This
mutation abolishes the phosphorylation site used by eIF2a
kinases and deregulates eIF2 activity (Scheuner et al, 2001).
Despite expressing high levels of active Fv2E-PERK, AP20187-
treated eIF2aA/A cells have no phosphorylated eIF2a and are
unable to activate the downstream targets ATF4 and GADD34
(Figure 3D). Expression microarrays showed that the cluster
of genes induced by both Fv2E-PERK activation and by ER
stress in wild-type (eIF2aS/S) cells (Group A in Figure 3E)
failed to undergo induction in the Fv2E-PERK-expressing
mutant eIF2aA/A cells, thus establishing an essential role for
eIF2a phosphorylation in the activation of the ISR by Fv2E-
PERK.
A smaller subset of genes that were induced by ER stress
but not by Fv2E-PERK activation was also identified
(Figure 3E, Group B); these presumably represent targets
of parallel pathways active in the ER stress response
(Harding et al, 2002; Kaufman, 2002). A third category of
genes was prominently induced by activation of Fv2E-PERK
in wild-type eIF2aS/S cells, but less so by ER stress and not at
all in mutant eIF2aA/A cells. Among these were genes tran-
siently induced by Fv2E-PERK (higher at 4 h than at 8 h), a
subset that may be enriched in short-lived mRNAs stabilized
by translational repression, which peaks early in the
AP20187-treated wild-type eIF2aS/S cells but is later reversed
as GADD34 is induced. This mechanism of gene activation is
likely to be less important in tunicamycin-treated cells,
because of the gradual onset of eIF2a phosphorylation and
more modest translational repression effected by that drug
(Harding et al, 2000b). Such differences may account for the
larger number of genes activated by Fv2E-PERK than by
tunicamycin (data not shown and supplementary tables).
AP20187-induced Fv2E-PERK activation protects cells
against oxidative glutamate toxicity, peroxynitrite
donor and ER stress
Treatment of Fv2E-PERK-expressing HT22 cells with AP20187
for as little as 15min was sufficient to induce eIF2a phos-
phorylation (Figures 3B and 4A). Subsequent activation of
downstream gene expression was enhanced after the drug
Figure 4 Activation of Fv2E-PERK enhances survival of glutamate-exposed HT22 cells. (A) Immunoblot of Fv2E-PERK, phosphorylated eIF2a
(eIF2a-P), total eIF2a and the downstream target GADD34 in untreated cells (UT) and at various points of recovery following a 15-min
exposure to 1 or 2 nM AP20187. The position of the activated Fv2E-PERKP and inactive Fv2E-PERK0 proteins is indicated. (B) 35S-methionine
incorporation into newly synthesized proteins at various time points of recovery from translational inhibition by treatment for 15min with
1 nM AP20187 (circles) or 2 nM AP20187 (squares). Translation is expressed as the percentage of 35S-methionine incorporation into untreated
cells, which is arbitrarily set at 100%. (C) Survival of parental HT22 cells or cells expressing Fv2E-PERK that had been treated with 1 nM, or
2 nM AP20187 or ethanol carrier for 15min followed by 5 or 12 h of recovery and subsequently exposed to the indicated concentration of
glutamate for 24 h. 100% survival is defined as the MTT reduction in cells that had not been exposed to glutamate in each AP20187 treatment
group. The means7SEM of a representative experiment performed in duplicate and repeated four times are shown. (D) Photomicrographs of
crystal-violet-stained parental HT22 cells or cells expressing Fv2E-PERK treated with 1 or 2 nM AP20187 or ethanol carrier for 1 h followed by
5 h of recovery and subsequently exposed to glutamate for 24 h. The cells were switched to regular media for 6 days and then stained with
crystal violet.
Preconditioning by the integrated stress response
PD Lu et al
&2004 European Molecular Biology Organization The EMBO Journal VOL 23 | NO 1 | 2004 173
was withdrawn, as translation rates were recovering (Figure
4A and B). Thus, a short pulse of AP20187 followed by
withdrawal of the drug mimics the kinetic profile of a
response of cells to stress (Brostrom and Brostrom, 1998;
Novoa et al, 2003). Therefore, cells were exposed to AP20187
for 15min, the dimerizer was removed and, following a
variable recover period of 5 or 12 h, the cells were exposed
to glutamate. AP20187 pretreatment protected Fv2E-PERK-
expressing HT22 cells from subsequent exposure to gluta-
mate, but did not affect the survival of parental HT22 cells
(Figure 4C and D). The survival advantage of pretreatment
correlated with the dose of dimerizer used and was still
apparent 12 h after withdrawal of the dimerizer, a point at
which translation had recovered to nearly normal levels
(Figure 4B).
Oxidative glutamate toxicity is attributed to inhibited im-
port of cystine and consequent glutathione depletion, result-
ing in accumulation of endogenous peroxides (Murphy et al,
Name Description Genbank
Translation/amino acid transport and metabolism
Myd116 EIF2alpha phosphatase, mouse GADD34 X51829 1.70 ± 0.28 9.19 ± 0.35 12.97 ± 0.82 1.05 ± 0.09 0.93 ± 0.20 1.06 ± 0.07 0.06 ± 0.29 6.90 ± 0.13 0.45 ± 0.10 0.71 ± 0.38
Abcf2 ATP-binding cassette, subfamily F2 (GCN20) AI837318 3.97 ± 0.87 4.30 ± 0.48 8.13 ± 1.15 1.64 ± 0.01 1.70 ± 0.21 1.62 ± 0.23 0.09 ± 0.58 1.04 ± 0.04 0.59 ± 0.26 0.12 ± 0.09
Asns Asparagine synthetase AV253908 0.86 ± 0.15 3.90 ± 0.60 7.91 ± 1.95 1.11 ± 0.07 0.80 ± 0.01 0.94 ± 0.02 1.08 ± 0.35 2.07 ± 0.05 0.52 ± 0.04 1.29 ± 0.42
Mthfr 5,10-methylenetetrahydrofolate reductase AW214225 1.25 ± 0.20 9.84 ± 0.94 7.78 ± 0.38 1.16 ± 0.02 1.44 ± 0.16 0.91 ± 0.26 0.68 ± 0.26 1.51 ± 0.30 0.41 ± 0.25 0.97 ± 0.57
Slc1a4 Glutamate/neutral amino acids transporter U75215 1.96 ± 0.06 5.92 ± 0.26 6.51 ± 0.69 0.97 ± 0.02 1.32 ± 0.05 1.03 ± 0.01 0.96 ± 0.15 2.23 ± 0.71 0.16 ± 0.09 0.59 ± 0.40
Sars1 Seryl-aminoacyl-tRNA synthetase 1 AI837395 2.24 ± 0.84 3.28 ± 0.42 6.13 ± 1.07 1.37 ± 0.02 1.21 ± 0.13 1.15 ± 0.27 0.20 ± 0.29 1.80 ± 0.31 0.33 ± 0.06 0.97 ± 0.32
Cars Cysteinyl-tRNA synthetase AI848732 1.26 ± 0.37 5.21 ± 0.25 6.07 ± 0.89 1.11 ± 0.11 1.33 ± 0.07 1.02 ± 0.09 0.79 ± 0.26 1.95 ± 0.10 0.05 ± 0.20 0.54 ± 0.50
SYTC Threonyl-tRNA synthetase AI849620 1.66 ± 0.18 3.15 ± 0.00 4.74 ± 0.57 1.04 ± 0.20 1.10 ± 0.06 0.97 ± 0.02 0.80 ± 0.20 1.44 ± 0.02 0.58 ± 0.09 0.78 ± 0.34
Rps6ka2 Ribosomal protein S6 kinase, 90 kD, polypeptide 2 AJ131021 1.75 ± 0.24 3.65 ± 0.25 4.72 ± 1.01 0.90 ± 0.14 0.92 ± 0.14 0.74 ± 0.35 0.67 ± 0.29 1.80 ± 0.31 0.79 ± 0.01 0.92 ± 0.23
Lars Leucyl-tRNA synthetase AI844089 1.26 ± 0.17 2.35 ± 0.01 4.45 ± 0.62 1.19 ± 0.05 1.19 ± 0.01 1.10 ± 0.02 0.96 ± 0.14 1.89 ± 0.12 0.63 ± 0.03 0.92 ± 0.03
Eprs Glutamyl-prolyl-tRNA synthetase X54327 1.73 ± 0.34 2.28 ± 0.31 4.39 ± 0.35 1.08 ± 0.07 1.18 ± 0.12 1.32 ± 0.07 0.99 ± 0.20 1.71 ± 0.27 0.52 ± 0.04 0.76 ± 0.04
Pycs Pyrroline-5-carboxylate synthetase AW124889 1.86 ± 0.59 3.15 ± 0.07 4.32 ± 0.09 1.05 ± 0.08 1.04 ± 0.05 0.93 ± 0.06 0.76 ± 0.18 2.08 ± 0.14 0.56 ± 0.09 0.93 ± 0.23
Nars Asparaginyl-tRNA synthetase AW125874 1.76 ± 0.27 2.63 ± 0.04 4.21 ± 0.86 1.50 ± 0.07 1.44 ± 0.04 1.12 ± 0.18 0.95 ± 0.27 1.64 ± 0.22 0.64 ± 0.06 0.83 ± 0.02
WRS Alpha-2 subunit; tryptophanyl-tRNA synthetase X69656 2.00 ± 0.26 2.39 ± 0.17 4.06 ± 0.65 1.05 ± 0.06 1.10 ± 0.06 0.98 ± 0.02 0.73 ± 0.39 3.06 ± 0.30 0.30 ± 0.08 0.29 ± 0.10
Aars Alanyl-tRNA synthetase AI839392 1.73 ± 0.36 3.13 ± 0.15 4.01 ± 0.32 1.06 ± 0.06 1.05 ± 0.12 0.86 ± 0.14 0.67 ± 0.05 1.52 ± 0.06 0.60 ± 0.12 1.00 ± 0.12
Eif4ebp1 EIF4E binding protein 1 U28656 1.66 ± 0.48 2.80 ± 0.23 3.82 ± 0.56 1.02 ± 0.01 1.02 ± 0.00 0.86 ± 0.17 0.77 ± 0.14 1.55 ± 0.19 0.49 ± 0.12 0.87 ± 0.33
EST Phosphoserine phosphatase homologue AI846545 1.34 ± 0.22 2.54 ± 0.23 3.74 ± 0.37 1.30 ± 0.12 1.21 ± 0.09 1.12 ± 0.32 0.87 ± 0.17 1.57 ± 0.04 0.54 ± 0.07 0.96 ± 0.06
Yars Tyrosyl-tRNA synthetase AW122542 1.33 ± 0.56 2.85 ± 0.24 3.59 ± 0.24 1.11 ± 0.17 1.14 ± 0.13 1.03 ± 0.04 0.96 ± 0.06 1.59 ± 0.15 0.85 ± 0.11 1.08 ± 0.12
Elp3 Elongation protein 3 homolog (S. cerevisiae) AI851229 1.45 ± 0.16 1.47 ± 0.28 2.91 ± 0.06 1.00 ± 0.04 1.16 ± 0.04 1.06 ± 0.03 0.26 ± 0.11 1.04 ± 0.03 0.70 ± 0.02 0.47 ± 0.01
EST Isoleucyl-tRNA synthetase AI848393 1.23 ± 0.15 2.30 ± 0.05 2.79 ± 0.27 0.82 ± 0.10 0.85 ± 0.14 0.75 ± 0.10 0.78 ± 0.11 1.23 ± 0.07 0.68 ± 0.03 1.00 ± 0.03
Slc1a7 Neutral amino acid transporter, ASCT2 L42115 1.16 ± 0.27 1.78 ± 0.42 2.39 ± 0.20 1.08 ± 0.24 1.11 ± 0.05 1.17 ± 0.05 0.72 ± 0.36 1.45 ± 0.00 0.11 ± 0.83 0.24 ± 0.55
Shmt2 Serine hydroxymethyl transferase 2 AV009978 1.02 ± 0.01 1.47 ± 0.01 2.34 ± 0.45 0.78 ± 0.07 0.86 ± 0.14 0.86 ± 0.06 0.70 ± 0.34 1.67 ± 0.48 0.42 ± 0.03 0.80 ± 0.77
Stress response
EST UVRAG homologue, UV radiation resistance AI020259 21.66 ± 5.89 64.05 ± 9.26 49.58 ± 14.9 4.35 ± 0.05 4.89 ± 0.17 4.08 ± 0.77 0.01 ± 0.00 0.07 ± 0.37 0.10 ± 0.63 0.01 ± 0.00
Gch GTP cyclohydrolase 1 L09737 2.98 ± 1.05 12.96 ± 1.15 21.76 ± 0.80 0.88 ± 0.16 0.68 ± 0.02 0.63 ± 0.36 0.62 ± 0.06 3.24 ± 0.91 0.93 ± 0.15 0.47 ± 0.52
GADD45 Mus musculus GADD45 protein (gadd45) gene U00937 2.74 ± 0.06 21.42 ± 0.42 20.24 ± 0.34 1.11 ± 0.10 1.27 ± 0.10 0.92 ± 0.00 0.65 ± 0.55 10.25 ± 1.16 0.24 ± 0.06 0.44 ± 0.40
Ndr1 N-myc downstream regulated 1 U60593 5.76 ± 1.82 9.26 ± 0.70 14.09 ± 2.25 1.02 ± 0.24 1.01 ± 0.35 1.05 ± 0.35 0.67 ± 0.11 2.94 ± 0.55 0.59 ± 0.04 0.85 ± 0.47
Sqstm1 Sequestosome 1; A170, STAP U40930 1.97 ± 0.98 4.31 ± 0.65 6.11 ± 0.59 1.21 ± 0.04 1.26 ± 0.29 1.26 ± 0.01 0.56 ± 0.17 1.74 ± 0.08 0.31 ± 0.35 0.65 ± 0.43
Arnt3 Aryl hydrocarbon receptor nuclear translocator-like AB014494 1.18 ± 0.08 3.08 ± 0.21 3.04 ± 0.03 0.95 ± 0.09 1.06 ± 0.08 0.80 ± 0.23 0.35 ± 0.03 1.10 ± 0.10 0.56 ± 0.11 0.54 ± 0.04
Dnajb9 DnaJ (Hsp40) homolog, subfamily B, member 9 AI835630 1.00 ± 0.03 1.86 ± 0.10 2.90 ± 0.02 0.88 ± 0.19 0.91 ± 0.22 0.78 ± 0.56 0.69 ± 0.26 3.74 ± 0.28 0.17 ± 0.05 0.58 ± 0.09
Tbce Tubulin-specific chaperone e AI852161 1.25 ± 0.02 3.40 ± 0.03 2.82 ± 0.34 1.44 ± 0.01 1.45 ± 0.17 0.98 ± 0.31 0.70 ± 0.13 1.08 ± 0.06 0.41 ± 0.50 0.57 ± 0.45
Clcn3 Chloride channel 3 AF029347 0.77 ± 0.13 1.55 ± 0.70 1.96 ± 0.26 0.98 ± 0.13 1.20 ± 0.09 0.86 ± 0.03 0.09 ± 0.57 1.69 ± 0.06 1.04 ± 0.34 1.67 ± 0.03
Dnajc3 DnaJ (Hsp40) homolog, subfamily C, member 3, p58U28423 0.28 ± 0.03 0.80 ± 0.00 1.06 ± 0.18 0.77 ± 0.24 0.85 ± 0.39 0.76 ± 0.05 1.24 ± 0.27 6.50 ± 1.69 0.52 ± 0.00 1.24 ± 0.07
Redox/detox
Pon2 Paraoxonase 2;  esterase;  antilipid oxidation L48514 8.21 ± 0.54 12.74 ± 1.77 17.43 ± 1.80 2.62 0.31 2.973 ± 0.09 2.180 ± 0.67 0.09 ± 0.52 0.09 ± 0.55 1.06 ± 0.92 1.67 ± 0.78
B5R.1 NADH-cytochrome B5 reductase AI839690 2.80 ± 0.17 4.60 ± 0.26 10.00 ± 1.51 1.06 ± 0.00 1.135 ± 0.18 0.924 ± 0.40 0.98 ± 0.27 3.15 ± 0.33 0.44 ± 0.01 0.57 ± 0.18
EST Thioredoxin-like protein HT014 homologue AA798365 1.33 ± 0.13 3.23 ± 0.00 3.16 ± 0.34 1.90 ± 0.03 1.894 ± 0.29 1.196 ± 0.51 0.37 ± 0.07 0.75 ± 0.35 0.73 ± 0.28 0.60 ± 0.36
Txnip Thioredoxin interacting protein AI839138 0.88 ± 0.23 2.17 ± 0.05 2.28 ± 0.25 1.08 ± 0.03 1.307 ± 0.10 0.879 ± 0.31 0.64 ± 0.43 1.43 ± 0.26 0.40 ± 0.05 0.51 ± 0.40
Cpo Coproporphyrinogen oxidase D16333 0.78 ± 0.05 1.64 ± 0.02 1.83 ± 0.02 0.88 ± 0.36 1.063 ± 0.02 0.929 ± 0.18 0.95 ± 0.44 3.31 ± 0.34 0.42 ± 0.02 1.00 ± 0.11
Protein degradation
Siah2 Seven in absentia 2; ubiquitin ligase Z19581 1.19 ± 0.08 3.52 ± 0.09 3.45 ± 0.50 0.88 ± 0.01 0.937 ± 0.09 0.952 ± 0.05 0.80 ± 0.02 2.63 ± 0.33 0.89 ± 0.10 0.41 ± 0.49
Fbxo8 f-box only protein 8 AI844932 0.97 ± 0.45 2.34 ± 0.62 2.92 ± 0.33 2.38 0.58 1.828 ± 0.29 1.182 ± 0.26 0.69 ± 0.34 1.17 ± 0.22 0.65 ± 0.01 1.15 ± 0.09
Ctsc Cathepsin C U74683 1.06 ± 0.23 1.10 ± 0.01 2.24 ± 0.10 0.33 0.12 0.295 ± 0.05 0.136 ± 0.09 0.53 ± 1.15 0.84 ± 0.92 0.32 ± 0.20 0.31 ± 0.57
Secretory pathway
Wfs1 Wolfram syndrome 1 homolog, ER localized AF084482 2.71 ± 0.42 3.45 ± 0.15 7.75 ± 0.51 1.12 ± 0.23 1.185 ± 0.24 0.990 ± 0.26 0.06 ± 0.27 5.64 ± 0.09 0.04 ± 0.09 0.73 ± 0.05
Spaf Transitional endoplasmic reticulum ATPase AF016544 2.00 ± 0.28 3.12 ± 0.06 4.74 ± 0.51 1.00 ± 0.02 0.877 ± 0.11 0.728 ± 0.13 0.27 ± 0.16 0.90 ± 0.32 0.65 ± 0.18 0.34 ± 0.25
Herpud1 Homocysteine-inducible-ubiquitin-like domain 1 AI846938 1.07 ± 0.15 4.28 ± 0.19 3.11 ± 0.17 0.94 ± 0.07 0.898 ± 0.14 0.686 ± 0.17 0.38 ± 0.33 3.84 ± 0.33 0.19 ± 0.07 0.74 ± 0.17
Ero1l Endoplasmic reticulum oxidoreductin 1-like AA798624 1.00 ± 0.14 1.91 ± 0.26 2.59 ± 0.33 0.92 ± 0.10 1.065 ± 0.08 1.066 ± 0.23 0.52 ± 0.47 2.03 ± 0.02 0.72 ± 0.21 1.13 ± 0.12
Sel1h Sel1 (suppressor of lin-12) 1 homologue AW121840 0.79 ± 0.43 1.04 ± 0.30 2.19 ± 0.73 1.04 ± 0.01 0.887 ± 0.11 1.029 ± 0.12 0.77 ± 0.56 5.96 ± 4.70 0.20 ± 0.04 0.35 ± 0.12
ERO1Lb Endoplasmic reticulum oxidoreductin 1-like-beta AI049144 0.27 ± 0.04 0.81 ± 0.15 1.09 ± 0.02 0.77 ± 0.08 0.823 ± 0.05 0.599 ± 0.10 0.89 ± 0.26 4.02 ± 0.57 0.68 ± 0.16 1.44 ± 0.54
Transcription
Atf3 Activating transcription factor 3 U19118 2.54 ± 0.26 24.52 ± 1.62 15.21 ± 1.69 0.92 ± 0.10 1.041 ± 0.18 0.881 ± 0.08 0.73 ± 0.08 3.35 ± 0.57 0.64 ± 0.28 0.94 ± 0.14
Nrbf1 Nuclear receptor binding factor 1 AW046483 4.30 ± 0.56 4.74 ± 0.55 8.75 ± 0.11 2.41 ± 0.26 2.378 ± 0.24 1.855 ± 0.87 0.03 ± 0.06 1.68 ± 1.71 0.11 ± 0.80 0.06 ± 0.28
Nfkb2 Nuclear factor of kappa  B cell 2 AW047899 3.27 ± 0.23 6.45 ± 0.32 8.26 ± 1.04 0.99 ± 0.01 0.971 ± 0.13 1.043 ± 0.08 0.38 ± 0.09 0.80 ± 0 0.94 ± 0.11 0.86 ± 0.15
Atf5 Activating transcription factor 5 AB012276 2.22 ± 0.27 5.79 ± 0.26 7.54 ± 2.44 1.36 ± 0.04 1.365 ± 0.33 1.050 ± 0.13 0.99 ± 0.21 2.80 ± 0.56 0.23 ± 0.12 0.37 ± 0.35
Chop-10 Transcription factor CHOP, GADD153 X67083 0.98 ± 0.08 4.35 ± 0.65 6.41 ± 0.25 1.10 ± 0.27 1.176 ± 0.15 0.940 ± 0.19 0.60 ± 0.34 11.30 ± 0.07 0.49 ± 0.05 0.75 ± 0.27
Nupr1 Nuclear protein 1 AI852641 1.36 ± 0.23 5.85 ± 0.47 6.29 ± 1.64 1.26 ± 0.17 1.449 ± 0.32 1.119 ± 0.16 1.22 ± 0.75 3.37 ± 0.39 0.02 ± 0.01 0.59 ± 0.25
Cebpg CCAAT/enhancer binding protein (C/EBP), gamma AB012273 1.94 ± 0.22 6.31 ± 0.39 5.96 ± 0.12 1.07 ± 0.03 1.068 ± 0.01 0.906 ± 0.07 0.89 ± 0.25 1.75 ± 0.09 0.52 ± 0.29 0.60 ± 0.19
Relb (v-rel) oncogene related B M83380 2.60 ± 0.02 9.02 ± 0.60 5.87 ± 1.42 0.90 ± 0.07 1.054 ± 0.09 1.182 ± 0.27 0.56 ± 0.21 1.00 ± 0.41 0.68 ± 0.09 0.68 ± 0.00
Tbpl1 TATA box binding protein-like 1 AB017697 1.79 ± 0.17 3.42 ± 0.11 5.63 ± 0.45 1.89 ± 0.27 2.069 ± 0.05 1.415 ± 0.53 0.55 ± 0.47 1.08 ± 0.08 0.55 ± 0.20 0.54 ± 0.13
Cebpb CCAAT/enhancer binding protein (C/EBP), beta M61007 2.10 ± 0.37 3.31 ± 0.41 4.23 ± 0.68 1.02 ± 0.03 0.952 ± 0.07 1.099 ± 0.30 0.98 ± 0.30 1.96 ± 0.05 0.48 ± 0.02 0.55 ± 0.13
Cbx4 Chromobox homolog 4, transcriptional repressor U63387 1.48 ± 0.37 3.07 ± 0.08 4.16 ± 0.88 1.17 ± 0.03 1.111 ± 0.23 1.107 ± 0.10 0.91 ± 0.10 1.98 ± 0.41 0.61 ± 0.19 0.91 ± 0.01
SKiP Ski-interacting protein, nuclear receptor coactivator AW046671 1.91 ± 0.60 2.84 ± 0.23 3.87 ± 0.09 1.16 ± 0.01 1.319 ± 0.28 0.973 ± 0.13 0.55 ± 0.22 1.15 ± 0.20 0.75 ± 0.11 0.65 ± 0.17
ATF6 ATF6 alpha homologue AA592069 1.32 ± 0.30 2.05 ± 0.24 3.85 ± 0.81 0.83 ± 0.39 0.979 ± 0.15 1.059 ± 0.14 0.30 ± 0.14 1.86 ± 0.01 0.48 ± 0.07 0.30 ± 0.08
Atf4 Activating transcription factor 4 M94087 1.62 ± 0.13 3.01 ± 0.18 3.60 ± 0.61 0.85 ± 0.08 1.012 ± 0.02 1.045 ± 0.06 0.84 ± 0.02 1.80 ± 0.02 0.52 ± 0.15 0.99 ± 0.19
Nfil3; E4BP NFIL3/E4BP4 transcription factor U83148 1.51 ± 0.13 4.29 ± 0.49 3.56 ± 0.37 0.87 ± 0.16 0.927 ± 0.19 0.756 ± 0.31 0.60 ± 0.09 1.92 ± 0.08 0.28 ± 0.03 0.29 ± 0.01
Lmo4 LIM only 4; transcriptional regulator cofactor AF074600 0.94 ± 0.27 2.98 ± 0.06 3.47 ± 0.15 1.16 ± 0.32 1.108 ± 0.21 0.976 ± 0.20 0.41 ± 0.07 1.18 ± 0.54 0.24 ± 0.24 0.31 ± 0.06
Klf4 Kruppel-like factor 4 (gut) U20344 1.17 ± 0.02 3.58 ± 0.03 2.74 ± 0.02 0.97 ± 0.01 1.070 ± 0.07 0.770 ± 0.08 0.85 ± 0.43 1.82 ± 0.55 0.24 ± 0.33 0.35 ± 0.49
Xbp1 X-box binding protein 1 AW123880 1.00 ± 0.06 2.64 ± 0.32 2.65 ± 0.29 1.07 ± 0.06 0.950 ± 0.03 0.735 ± 0.19 0.63 ± 0.14 1.14 ± 0.12 0.12 ± 0.01 0.36 ± 0.00
Ets2 E26 avian leukemia oncogene 2, 3' domain J04103 1.22 ± 0.38 2.17 ± 0.28 2.41 ± 0.38 1.00 ± 0.06 1.028 ± 0.22 0.881 ± 0.10 0.66 ± 0.04 1.49 ± 0.17 0.37 ± 0.18 0.28 ± 0.01
Rxrip110 Retinoid X receptor interacting protein 110 U22015 0.68 ± 0.12 1.52 ± 0.07 1.74 ± 0.49 1.01 ± 0.01 1.013 ± 0.01 0.888 ± 0.11 0.53 ± 0.18 1.19 ± 0.10 0.97 ± 0.10 1.17 ± 0.71
Genes induced at least 2-fold at 8 h in AP20187 treated Fv2e-PERK and 1.5-fold in tunicamycin treated wildtype (WT) cells. The genes have been grouped into functional categories six of which are shown here. (A complete list of all 506 genes  
activated at least two-fold by AP20187 treatment is provided in Supplementary tables 1 and 2). The mean ± the average deviation of the normalized signal from treated to untreated cells from two independent experiments is shown. 
eIF2α (S/S) Fv2E-PERK eIF2α (A/A) Fv2E-PERK Perk +/+ Perk−/−
AP20187 AP20187 Tunicamycin
4 h 8 h 0 h 6 h0 h 4 h 8 h 0 h
Tunicamycin
6 h0 h
Table I Expression level of genes induced at least two-fold at 8 h in AP20187-treated Fv2E-PERK and 1.5-fold in tunicamycin-treated wild-type
(WT) cells. The expression level of the same genes in AP20187-treated Fv2E-PERK expressing mutant eIF2aA/A cells and tunicamycin-treated
Perk/ cells is shown for comparison. The genes have been grouped into functional categories, six of which are shown here. (A complete list
of all 506 genes activated at least two-fold by AP20187 treatment is provided in a supplementary table.) The mean7average deviation of the
expression level (normalized signal strength, see Methods) in untreated and treated cells from two independent experiments is shown
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1989). To determine if eIF2a phosphorylation affects the
development of oxidative stress or acts downstream of it,
we measured levels of endogenous peroxides induced by
glutamate using dichlorofluorescin (DCF), a cell-permeant
molecule that is oxidized by endogenous peroxides and
other oxidants to the fluorescent dichlorofluoresceine.
AP20187 had no measurable effect on DCF fluorescence in
parental HT22 cells (Figure 5A and B) whereas glutamate
treatment resulted in a profound increase in DCF fluorescence
as detected by FACscan (Figure 5C and D). DCF fluorescence
levels fell only when the cells died, an event reflected by
permeability to propidium iodide (Figure 5 A–D).
AP20187 pretreatment of Fv2E-expressing cells did not
affect DCF fluorescence in cells that were not exposed to
glutamate (Figure 5E and F), but markedly reduced DCF
fluorescence in the cells exposed to glutamate (Figure 5G
and H). Treatment with AP20187 caused some death among
the Fv2E-PERK-expressing cells (compare the upper left
quadrants in Figure 5E and F), as predicted by the pro-
apoptotic effects of another eIF2a kinase PKR (Srivastava
et al, 1998). However, in cells exposed to glutamate, AP20187
dramatically reduced the fraction of propidium iodide posi-
tive (dead) cells (compare the upper left quadrants in Figure
5G and H). AP20187 pretreatment also protects against
glutamate-induced glutathione depletion (Figure 5I). The
latter observation links the protective effect of the eIF2a
phosphorylation induced by Fv2E-PERK to the previously
established role of oxidative glutamate toxicity in glutathione
depletion (Tan et al, 1998a). These experiments show that
activation of an eIF2a kinase prevents oxidative stress and
cell death in HT22 cells exposed to glutamate.
To measure the effect of Fv2E-PERK activation on the
sensitivity of cells to other stressful conditions, we introduced
the transgene into immortalized mouse embryo fibroblasts,
which are sensitive to both ER stress and nitrosative stress. In
these cells too, AP20187 treatment activated Fv2E-PERK,
phosphorylated eIF2a and activated downstream genes.
This is apparent in wild-type cells and even more so in
Perk/ cells which, lacking the endogenous eIF2a kinase
activity, were able to tolerate higher levels of Fv2E-PERK
(Figure 6A and B). AP20187 protected the Fv2E-PERK trans-
genic cells with a wild-type eIF2a genotype (eIF2aS/S) against
the lethal effects of the ER stress-inducing agent tunicamycin
and the peroxinitrite donor SIN-1 (Figure 6C and D). No
protection was afforded by AP20187 to the Fv2E-PERK trans-
genic cells with the serine 51 to alanine mutation in eIF2a
(eIF2aA/A).
Discussion
Phosphorylation of eIF2a impacts on the cell at two levels: it
reduces the rate of translation initiation and with it protein
Figure 5 AP20187-mediated activation of Fv2E-PERK reduces the
levels of glutamate-induced endogenous peroxides and rescues
glutamate-induced glutathione depletion. Dual-channel FACscans
of dichlorofluorescein fluorescence (X-axis) and propidium iodide
fluorescence (Y-axis) of parental HT22 cells (A–D) or Fv2E-PERK
cells (E–H) that were either mock pretreated (A, C, E, G) or
pretreated with 1 nM AP20187 for 1 h followed by a 5h recovery
period (B, D, F, H) before exposure to 5mM glutamate for 10 h (C,
D, G, H) are shown. The fraction of cells in each quadrant of the
two-dimensional FACscan is displayed in the table below.
A (%) B (%) C (%) D (%) E (%) F (%) G (%) H (%)
Upper lt 0.78 1.23 32.53 32.86 1.28 5.93 33.61 7.39
Upper rt 0.09 0.19 15.44 16.31 0.17 0.23 8.10 0.73
Lower lt 97.31 96.35 27.14 23.87 95.84 92.92 28.45 87.26
Lower rt 1.82 2.24 24.90 26.96 2.72 0.92 29.84 4.62
(I) Glutathione levels in HT22 cells expressing Fv2E-PERK either
mock pretreated or pretreated with 1 nM AP20187 followed by a 5h
recovery period. Glutathione levels were measured at various points
after exposure to 5mM glutamate or at 10 h postrecovery in the
absence of glutamate. The means7SEM (n¼ 2) are shown.
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synthesis while at the same time activating a gene expression
program, which we refer to as the ISR. Both effects may
contribute to cytoprotection. By blocking new protein synth-
esis, eIF2a phosphorylation may conserve energy, divert
cysteine, glycine and glutamate to glutathione biosynthesis,
and potentially prevent the synthesis of pro-apoptotic pro-
teins. Indeed the protein synthesis inhibitor cycloheximide
has been shown to protect neuronal cells from glutamate
(Tan et al, 1998a, b). However, translational repression is not
the only mechanism by which eIF2a phosphorylation pro-
motes resistance to glutamate, as transient Fv2E-PERK acti-
vation is able to protect cells against glutamate exposure even
when the latter occurs after phosphorylated eIF2a has fallen
to basal levels and protein synthesis has recovered (Figure 4).
The target genes of the ISR include membrane transporters
for cystine and glycine, as well as several enzymes involved
in glutathione biosynthesis. EIF2a phosphorylation and acti-
vation of the ISR is therefore likely to reduce levels of reactive
oxygen species by promoting the capacity of cells to synthe-
size glutathione. This conclusion is supported by higher
levels of glutathione found in AP20187-treated Fv2E-PERK
cells (Figure 5I) and by the observation that a mutation that
stably reduces eIF2a levels in HT22 cells increases levels of
g-glutamyl cysteine synthetase, a key enzyme in glutathione
biosynthesis (Tan et al, 2001). Several other oxidative stress
response genes are also targets of the ISR (Harding et al,
2003) and are activated by Fv2E-PERK (Table I). As reactive
oxygen species play a role in cell death in glutamate toxicity,
ER stress and nitrosative stress, the persistent survival benefit
afforded to HT22 cells, 12 h after transient activation of Fv2E-
PERK, is likely to be mediated by the gene products of the ISR.
Levels of phosphorylated eIF2a are comparable in cells
following activation of Fv2E-PERK and exposure to tunica-
mycin or thapsigargin (Figures 1B and 3B), and pretreatment
with the stress-inducing agents provides similar levels of
resistance to glutamate (compare Figures 1A and 4C).
Furthermore, inhibiting eIF2a phosphorylation by overex-
pression of a phosphatase (GADD34) sensitizes HT22 cells
to glutamate. Together these observations suggest that the ISR
is an important component of heterologous preconditioning
against oxidative glutamate toxicity. It is formally possible
that some of the benefits accrued by activating Fv2E-PERK
are mediated by pathways independent of the ISR and that
GADD34 overexpression has additional sensitizing effects
that are independent of eIF2a dephosphorylation. However,
we regard these unlikely possibilities because PERK has no
other known substrates, and a mutation in eIF2a that pre-
vents it from being phosphorylated abolishes the effects of
Fv2E-PERK activation.
Not all the target genes of the ISR promote cell survival.
CHOP, a well-characterized target of the ISR, contributes to
the susceptibility to cell death, as its overexpression kills cells
(McCullough et al, 2001) and its deletion protects from cell
death (Zinszner et al, 1998). Activation of such death-pro-
moting ISR targets may account for the weak toxicity of Fv2E-
PERK activation revealed in Figure 5F. Furthermore, transla-
tional inhibition, which is inherent to eIF2a phosphoryla-
tion, is incompatible with normal physiological activity and
Figure 6 AP20187-induced activation of Fv2E-PERK in MEFs is protective against ER stress and nitrosylation stress. (A) Immunoblot of Fv2E-
PERK from Wildtype (Perkþ /þ ) and Perk/ cells selected for stable expression of Fv2E-PERK and treated with 1 nM AP20187 for the
indicated periods of time. The positions of the activated and phosphorylated (Fv2E-PERKP) and the inactive hypophosphorylated Fv2E-PERK
(Fv2E-PERK0) are indicated. (B) Immunoblot analysis of immunoprecipitated endogenous PERK, phosphorylated eIF2a (eIF2a-P), total eIF2a,
ATF4, and CHOP from Perkþ /þ and Perk/ cells expressing Fv2E-PERK and treated with 1 nM AP20187 or 400 nM thapsigargin (Tg). The
positions of the activated and phosphorylated (endogenous PERKP) and the inactive hypophosphorylated PERK (endogenous PERK0) are
indicated. (C) Photomicrographs of crystal-violet-stained cells with wild-type (S/S) or mutant (A/A) eIF2a genotypes expressing Fv2E-PERK
treated with AP20187 or ethanol carrier prior to exposure to tunicamycin (Tm) for 16 h as described in Methods. The media were replaced after
tunicamycin exposure and the cells were stained with crystal violet 6 days later. (D) Survival of cells with wild-type (S/S) or mutant (A/A)
eIF2a genotypes expressing Fv2E-PERK that had been pretreated with 1 nM AP20187 or ethanol carrier and exposed to SIN-1 at the indicated
concentrations. 100% survival is defined as the MTT reduction in cells that had not been exposed to SIN-1. The means7SEM of a
representative experiment performed in triplicate and repeated twice are shown.
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persistent suppression of protein synthesis may also contri-
bute to cell death caused by Fv2E-PERK activation. It is
interesting however that persistent activation of the ISR is
tolerated for extended periods in the context of hibernation, a
physiologically quiescent stress-resistant state (Frerichs et al,
1994, 1998).
The data presented in this paper indicate that activation of
pathways downstream of eIF2a phosphorylation may be
protective against diverse conditions associated with oxida-
tive stress. Therefore, pharmacological agents that promote
eIF2a phosphorylation without adding to cell stress may be
useful in a wide range of clinical situations in anticipation
of cellular injury. By effecting an artificial hibernation-
like stress-resistant state, drugs based on this physiological
principle may be used to prevent cell injury in a variety
of clinical contexts. These include post-cardiac bypass
neurological injury, stroke-in-evolution, head trauma and
possibly preserve peripheral organs during procurement for
transplantation.
Methods
Cell culture and generation of stable cell lines
The HT22 subclone of HT-4 cells were a kind gift of Pamela Maher,
and were maintained at approximately 50% confluence in regular
media consisting of DMEM (Life Science Technologies), 10% fetal
calf serum (FCS, Atlanta Biologicals), 1 pen/strep and 2mM
L-glutamine (Life Science Technologies) as described (Maher and
Davis, 1996). Wildtype, Perk/ and eIF2aA/A MEFs immortalized
with SV40 large T antigen were grown in the same medium
(Harding et al, 2000b; Scheuner et al, 2001).
Cells expressing active GADD34 were produced by transducing
HT22 cells with pBabe, a retrovirus encoding the active A1 fragment
of hamster GADD34 (Novoa et al, 2001). GADD34DC-overexpressing
cells were made by transducing HT22 cells with retrovirus encoding
the inactive GADD34 mutant lacking the C-terminal 121 amino
acids, which contain the domain required for binding the catalytic
subunit of the phosphatase. The transduced HT22 cells were
selected for stable expression of the GADD34 fragments with 4 mg/
ml puromycin (Calbiochem) and maintained in regular media
supplemented with 55mM bME and 1 MEM non-essential amino
acids (NEAA) from Life Technologies. The level of expression of the
active A1 fragment of GADD34 in pools of transduced cells used in
these experiments was similar to that observed previously and is
estimated to be several fold higher than the endogenous levels in
stressed cells (Novoa et al, 2001).
The use of FK506 binding domains to create drug-activated
fusion proteins has previously been described (Spencer et al, 1993).
A modified version of the FK506 binding domain has recently been
engineered to bind specifically to a synthetic dimerization-inducing
ligand, AP20187, which is incapable of interacting with endogenous
FK506 binding proteins (www.ariad.com/regulationkits). The
Fv2E-PERK construct was made using the ARIAD Regulated
Homodimerization Kit. Briefly, the portion of the mouse Perk cDNA
encoding the kinase domain kinase domain (amino acids 537–1114)
was fused to two tandem modified FK506 binding domains (Fv2E)
from the pC4M-Fv2E plasmid. The 5
0 myristoylation signal encoded
in pC4M-Fv2E was removed and the Fv2E-PERK transgene was
shuttled into a retroviral vector, pBabe (Morgenstern and Land,
1990), and used to produce replication-defective retrovirus as
previously described (Landau and Littman, 1992). HT22 cells,
Wildtype MEFs, Perk/ MEFs and eIF2aA/A MEFs were trans-
duced with pBabe retrovirus encoding Fv2E-PERK, plated to clonal
dilution, and selected for stable expression of the transgene by the
addition of 4 and 2.5mg/ml puromycin, respectively. Levels of Fv2E-
PERK were consistently higher in pools of transduced Perk/
MEFs and eIF2aA/A MEFs than in the wild-type MEFs and the
mutant cells stably express the transgene at high levels, whereas the
wild-type cells tend to lose expression over time. These observa-
tions may reflect low levels of basal activity of the chimeric kinase
(leak), which is well tolerated by cells lacking endogenous kinase
activity (Perk/) and in cells with a mutant target (eIF2aA/A)
but is poorly tolerated by the wild-type cells. Several cell lines
expressing equal levels of Fv2E-PERK were established from the
clonal populations and these were used in the functional studies
shown in Figures 3 and 6. All the assays described in this
manuscript were performed in at least two different Fv2E-PERK
cell lines and in the parental cells. The data shown in the figures are
from representative cell lines.
Survival assays
Cells were plated at a density of 2.5–5.0103 cells/96-well plate
or 1.5–3.0104 cells/24-well plate. After pretreatment with
AP20187 (ARIAD) or mock pretreatment with an equal volume of
the carrier ethanol, HT22 cells were washed once in regular media
and then maintained in regular media for the duration of recovery.
Following the recovery period, the media were replaced with fresh
media containing L-glutamic acid (Sigma) for 24 h. MEFs were
mock pretreated or pretreated for 18 h with AP20187 and then
exposed to 3-morpholinosydnonimine (SIN-1, Sigma) for 6 h. The
cells were switched to media containing 0.5mg/ml MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide, Sigma) for
4 h and the reaction was stopped by the addition of an equal volume
of stop buffer (50% isopropanol, 10% SDS, 10 mM HCl). The
formazan crystals were allowed to dissolve during a 16h incubation
at 371C and the optical density was read at 550 nm. Experiments
were performed in duplicate or triplicate and repeated twice.
For the colony outgrowth assay, HT22 cells were plated at a
density of 1103 cells/6-well plate and maintained for 6 days in non-
supplemented media or media supplemented with 55mM bME. MEFs
were plated at a density of 5103 cells/6 well plate and pre-treated
with 1 nM AP20187 for 7 h, at which time tunicamycin was added for
an additional 16h (0.25mg/ml for wild type, eIF2aS/S cells and
0.025mg/ml for the mutant eIF2aA/A cells). The cells were allowed to
recover and resume growth and were fixed with 4% formaldehyde 6
days later prior to staining with crystal violet. The data shown are
representative wells from experiments repeated four times.
Array analysis
Two independently isolated Fv2E-PERK-expressing Perk/ trans-
formed MEF cell pools of each treatment group (0, 4, or 8 h with
2 nM AP20187) were used to isolate total RNA using the guanidine
thiocyanate–acid–phenol extraction method. The use of Perk/,
Fv2E-PERK(þ ) cells was favored because of the higher level of
Fv2E-PERK expression. The comparison group consisted of mutant
eIF2aA/A cells expressing comparable levels of Fv2E-PERK
(Figure 3D). Fluorescent labeled RNA probes for each of the
samples were prepared and hybridized to Affymetrix mouse
U74Av2 high-density oligonucleotide arrays as previously described
(Lockhart et al, 1996). Primary image analysis of the arrays was
performed using the Genechip 3.2 software package (Affymetrix,
Santa Clara, CA). The raw data from the hybridization experiments
were analyzed by GeneSpringTM. The raw signal strength from each
gene was normalized to the mean signal strength of all genes from
the same chip to obtain the normalized signal strength. Then, to
allow visualization of all data on the same scale for subsequent
analysis, the normalized signal strength of each gene was divided
by the median signal strength for that gene among all samples to
obtain the normalized expression level. The data were compared to
the results obtained from previously published data from wild type,
Perk/ or Atf4/ untreated or tunicamycin-treated samples
(Harding et al, 2003). Genes that were assigned a ‘present’ signal
flag (Genechip 3.2 software) in 8 h AP20187-treated Fv2E-PERK
samples or tunicamycin-treated wild-type cells and that had a raw
signal strength of greater than 50 in tunicamycin-treated wild-type
cells were further analyzed. In all, 653 genes that were induced two-
fold by either 4 or 8 h of AP20187 treatment of Fv2E-PERK cells or
by 6 h of tunicamycin treatment in wild-type fibroblasts were
identified; 506 of these were induced at least two-fold by AP20187
treatment in Fv2E-PERK cells and the remainder were induced by at
least two-fold in tunicamycin-treated wild-type cells and to varying
degrees in Fv2E-PERK cells (see Supplementary tables). The
complete data set has been submitted to the NCBI GEO database
Accession GDSH05.
Immunoblotting and translation assays
For analysis of Fv2E-PERK, eIF2a, ATF4, GADD34 and CHOP
by immunoblotting 6105 cells were plated onto 10 cm dishes
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16h prior to treatment. Cell extracts were prepared using harvest
buffer (10mM HEPES pH 8.0, 50mM NaCl, 0.5M sucrose, 0.1M
EDTA, 0.5% Triton X-100) containing both protease inhibitors
(1mM dithiothreitol (DTT), 2mg/ml pepstatin, 4mg/ml aprotinin,
100mM PMSF) and phosphatase inhibitors (10mM tetrasodium
pyrophosphate, 100mM NaF, 17.5mM b-glycerophosphate). The
low-speed supernatant (1000 g) containing cytoplasmic proteins
was collected and nuclear extracts were made by vortexing
the nuclei for 15min at 41C in buffer containing 20mM HEPES
pH 7.9, 400mM NaCl, 1mM EDTA, 1mM EGTA, 0.1% IGEPAL
CA-630, plus protease inhibitors. Equal amounts of protein were
loaded per lane in SDS–PAGE gels (30–50mg of cytoplasmic
extract, 20mg of nuclear extract). Immunoprecipitation procedures
for detecting endogenous PERK and immunoblotting procedures
for PERK, eIF2a, ATF4, GADD34 and CHOP have previously
been described (Bertolotti et al, 2000; Harding et al, 2000a, b;
Novoa et al, 2001).
To measure new protein synthesis, cells were labeled for 10min
with 50 mCi/ml 35S-Translabel (ICN) in pulse media (90% DMEM
without methionine and cysteine, 10% regular DMEM, 5% dialyzed
FCS, 1 pen/strep, 2mM L-glutamine). The dishes were flooded
with ice-cold PBS containing 1mM cycloheximide, 0.6mg/ml
L-methionine and 0.96mg/ml L-cysteine, washed twice in PBS,
and harvested in 1% Triton X-100-containing buffer as described
previously (Harding et al, 2000b). In all, 15mg of protein/lane was
loaded onto a 9% gel for detection of 35S-methionine incorporation
by autoradiography and 25 mg of protein/lane was loaded for
detection of Fv2E-PERK, eIF2a and GADD34 by immunoblot.
Assays for endogenous peroxides and glutathione
Parental HT22 and Fv2E-PERK-expressing cells were plated at
1105 cells/60mm dish and pretreated for 1 h with 1 nM AP20187
and allowed to recover in regular media for 5 h prior to the addition
of 5mM glutamate for 10 h. The media were removed to collect
floating cells and pooled with cells trypsinized from the dishes. The
cells were pelleted and resuspended in fresh media containing
10 mM 20,70-dichloro-dihydrofluorescin diacetate (DCF, Molecular
Probes) and incubated for 15min at 371C. Cells were then pelleted,
washed once in ice-cold PBS–2% FCS, and resuspended in PBS–2%
FCS containing 1mg/ml propidium iodide (PI, Roche). After a 5-min
incubation on ice, the cells were analyzed for DCF fluorescence
(FL-1, green channel) and PI positivity (FL-3, red channel) by a
Becton Dickson FACScan. In all, 10 000 ungated cells were counted.
Glutathione levels were measured using the modified DTNB-
GSSG reductase recycling assay (Griffith, 1980; Anderson, 1985).
Supplementary data
Supplementary data are available at The EMBO Journal Online.
Acknowledgements
We thank ARIAD Pharmaceuticals and Vic Rivera for supplying the
Fv2E expression vector and the AP20187 dimerizer drug, and Pam
Maher for the HT22 cells. This work was supported by NIH grants
ES08681 and DK47119 to DR and DK42394 to RJK. DR is an Ellison
Medical Foundation Senior Scholar in Aging.
References
Anderson ME 1985 Determination of glutathione and glutathione
disulfide in biological samples. Methods Enzymol 113: 548–555
Bertolotti A, Zhang Y, Hendershot L, Harding H, Ron D 2000
Dynamic interaction of BiP and the ER stress transducers in the
unfolded protein response. Nat Cell Biol 2: 326–332
Brostrom CO, Brostrom MA 1998 Regulation of translational initia-
tion during cellular responses to stress. Prog Nucleic Acid Res Mol
Biol 58: 79–125
Chen J 2000 Heme-regulated eIF2a kinase. In Translational Control
of Gene Expression, Sonenberg N, Hershey JWB, and Mathews
MB (eds) pp 529–546. Cold Spring Harbor: CSHL Press
Davis JB, Maher P 1994 Protein kinase C activation inhibits
glutamate-induced cytotoxicity in a neuronal cell line. Brain Res
652: 169–173
DeGracia DJ, Kumar R, Owen CR, Krause GS, White BC 2002
Molecular pathways of protein synthesis inhibition during brain
reperfusion: implications for neuronal survival or death. J Cereb
Blood Flow Metab 22: 127–141
Dever TE 2002 Gene-specific regulation by general translation
factors. Cell 108: 545–556
Frerichs KU, Hallenbeck JM 1998 Hibernation in ground squirrels
induces state and species-specific tolerance to hypoxia and
aglycemia: an in vitro study in hippocampal slices. J Cereb
Blood Flow Metab 18: 168–175
Frerichs KU, Kennedy C, Sokoloff L, Hallenbeck JM 1994 Local
cerebral blood flow during hibernation, a model of natural
tolerance to ‘cerebral ischemia’. J Cereb Blood Flow Metab 14:
193–205
Frerichs KU, Smith CB, Brenner M, DeGracia DJ, Krause GS,
Marrone L, Dever TE, Hallenbeck JM 1998 Suppression of protein
synthesis in brain during hibernation involves inhibition of
protein initiation and elongation. Proc Natl Acad Sci USA 95:
14511–14516
Griffith OW 1980 Determination of glutathione and glutathione
disulfide using glutathione reductase and 2-vinylpyridine. Anal
Biochem 106: 207–212
Harding H, Novoa I, Zhang Y, Zeng H, Wek RC, Schapira M, Ron D
2000a Regulated translation initiation controls stress-induced
gene expression in mammalian cells. Mol Cell 6: 1099–1108
Harding H, Zeng H, Zhang Y, Jungreis R, Chung P, Plesken H,
Sabatini D, Ron D 2001 Diabetes mellitus and exocrine pancreatic
dysfunction in Perk/ mice reveals a role for translational
control in survival of secretory cells. Mol Cell 7: 1153–1163
Harding H, Zhang Y, Bertolotti A, Zeng H, Ron D 2000b Perk is
essential for translational regulation and cell survival during the
unfolded protein response. Mol Cell 5: 897–904
Harding H, Zhang Y, Zeng H, Novoa I, Lu P, Calfon M, Sadri N, Yun
C, Popko B, Paules R, Stojdl D, Bell J, Hettmann T, Leiden J,
Ron D 2003 An integrated stress response regulates amino acid
metabolism and resistance to oxidative stress. Mol Cell 11:
619–633
Harding HP, Calfon M, Urano F, Novoa I, Ron D 2002
Transcriptional and translational control in the mammalian un-
folded protein response. Annu Rev Cell Dev Biol 18: 575–599
Hinnebusch AG 2000 Mechanism and regulation of initiator methio-
nyl-tRNA binding to ribosomes. In Translational Control of Gene
Expression, Sonenberg N, Hershey JWB, Mathews MB (eds)
pp 185–243. Cold Spring Harbor: CSHL Press
Kaufman RJ 2000 The double-stranded RNA-activated protein ki-
nase PKR. In Translational Control of Gene Expression, Sonenberg
N, Hershey JWB, Mathews MB (eds) pp 503–527. Cold Spring
Harbor: CSHL Press
Kaufman RJ 2002 Orchestrating the unfolded protein response in
health and disease. J Clin Invest 110: 1389–1398
Kumar R, Azam S, Sullivan J, Owen C, Cavener D, Zhang P,
Ron D, Harding H, Chen J, Han A, White B, Krause G,
DeGracia D 2001 Brain ischemia and reperfusion activates the
eukaryotic initiation factor 2a kinase, PERK. J Neurochem 77:
1418–1421
Landau N, Littman D 1992 Packaging system for rapid production of
murine leukemia virus vectors with variable tropism. J Virol 66:
5110–5113
Liu CY, Schroder M, Kaufman RJ 2000 Ligand-independent dimer-
ization activates the stress-response kinases IRE1 and PERK
in the lumen of the endoplasmic reticulum. J Biol Chem 275:
24881–24885
Lockhart DJ, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS,
Mittmann M, Wang C, Kobayashi M, Horton H, Brown EL 1996
Expression monitoring by hybridization to high-density oligonu-
cleotide arrays. Nat Biotechnol 14: 1675–1680
Maher P, Davis JB 1996 The role of monoamine metabolism in
oxidative glutamate toxicity. J Neurosci 16: 6394–6401
McCullough KD, Martindale JL, Klotz LO, Aw TY, Holbrook NJ 2001
Gadd153 sensitizes cells to endoplasmic reticulum stress by
down-regulating Bcl2 and perturbing the cellular redox state.
Mol Cell Biol 21: 1249–1259
Preconditioning by the integrated stress response
PD Lu et al
The EMBO Journal VOL 23 | NO 1 | 2004 &2004 European Molecular Biology Organization178
Miyamoto M, Murphy TH, Schnaar RL, Coyle JT 1989 Antioxidants
protect against glutamate-induced cytotoxicity in a neuronal cell
line. J Pharmacol Exp Ther 250: 1132–1140
Morgenstern JP, Land H 1990 Advanced mammalian gene transfer:
high titre retroviral vectors with multiple drug selection markers
and a complementary helper-free packaging cell line. Nucleic
Acids Res 18: 3587–3596
Morimoto BH, Koshland Jr DE 1990 Induction and expression of
long- and short-term neurosecretory potentiation in a neural cell
line. Neurone 5: 875–880
Murphy TH, Miyamoto M, Sastre A, Schnaar RL, Coyle JT 1989
Glutamate toxicity in a neuronal cell line involves inhibition
of cystine transport leading to oxidative stress. Neurone 2:
1547–1558
Novoa I, Zeng H, Harding H, Ron D 2001 Feedback inhibition of the
unfolded protein response by GADD34-mediated dephosphoryla-
tion of eIF2a. J Cell Biol 153: 1011–1022
Novoa I, Zhang Y, Zeng H, Jungreis R, Harding HP, Ron D 2003
Stress-induced gene expression requires programmed recovery
from translational repression. EMBO J 22: 1180–1187
Ron D, Harding H 2000 PERK and translational control by stress in
the endoplasmic reticulum. In Translational Control, Hershey J,
Mathews M, Sonenberg N (eds) pp 547–560. Cold Spring Harbor:
CSHL Press
Scheuner D, Song B, McEwen E, Gillespie P, Saunders T, Bonner-
Weir S, Kaufman RJ 2001 Translational control is required for the
unfolded protein response and in-vivo glucose homeostasis. Mol
Cell 7: 1165–1176
Schubert D, Piasecki D 2001 Oxidative glutamate toxicity can
be a component of the excitotoxicity cascade. J Neurosci 21:
7455–7462
Spencer DM, Wandless TJ, Schreiber SL, Crabtree GR 1993
Controlling signal transduction with synthetic ligands. Science
262: 1019–1024
Srivastava SP, Kumar KU, Kaufman RJ 1998 Phosphorylation of
eukaryotic translation initiation factor 2 mediates apoptosis in
response to activation of the double-stranded RNA-dependent
protein kinase. J Biol Chem 273: 2416–2423
Tan S, Sagara Y, Liu Y, Maher P, Schubert D 1998a The regulation of
reactive oxygen species production during programmed cell
death. J Cell Biol 141: 1423–1432
Tan S, Somia N, Maher P, Schubert D 2001 Regulation of antioxidant
metabolism by translation initiation factor 2alpha. J Cell Biol 152:
997–1006
Tan S, Wood M, Maher P 1998b Oxidative stress induces a form of
programmed cell death with characteristics of both apoptosis and
necrosis in neuronal cells. J Neurochem 71: 95–105
Zhang P, McGrath B, Li S, Frank A, Zambito F, Reinert J, Gannon
M, Ma K, McNaughton K, Cavener DR 2002a The PERK eukar-
yotic initiation factor 2 alpha kinase is required for the deve-
lopment of the skeletal system, postnatal growth, and the
function and viability of the pancreas. Mol Cell Biol 22:
3864–3874
Zhang P, McGrath BC, Reinert J, Olsen DS, Lei L, Gill S, Wek
SA, Vattem KM, Wek RC, Kimball SR, Jefferson LS, Cavener
DR 2002b The GCN2 eIF2alpha kinase is required for adapta-
tion to amino acid deprivation in mice. Mol Cell Biol 22:
6681–6688
Zinszner H, Kuroda M, Wang X, Batchvarova N, Lightfoot RT,
Remotti H, Stevens JL, Ron D 1998 CHOP is implicated in
programmed cell death in response to impaired function of the
endoplasmic reticulum. Genes Dev 12: 982–995
Preconditioning by the integrated stress response
PD Lu et al
&2004 European Molecular Biology Organization The EMBO Journal VOL 23 | NO 1 | 2004 179
